Bello Daniel, Jones Megan, Gadiyar Ishaan, Artim Laura, Blyth Sophia H, Brady Roscoe O, Vandekar Simon, Ward Heather Burrell
Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
JAMA Psychiatry. 2025 Jun 4. doi: 10.1001/jamapsychiatry.2025.0792.
IMPORTANCE: Transcranial magnetic stimulation (TMS), a form of noninvasive brain stimulation used to treat major depressive disorder, obsessive-compulsive disorder (OCD), and nicotine dependence, has well-established state-dependent effects on brain circuitry. However, a major question for TMS remains: does brain state affect clinical response? OBJECTIVE: To quantify the association between symptom provocation and clinical response to TMS for OCD and nicotine dependence, the only Food and Drug Administration-cleared TMS indications with symptom provocation. DATA SOURCES: PubMed, CINAHL, Embase, PsycInfo until August 30, 2024. STUDY SELECTION: Randomized clinical trials of TMS for OCD or nicotine dependence with a clinical outcome. Of 600 studies identified, 71 met inclusion criteria. DATA EXTRACTION AND SYNTHESIS: Data extraction was completed independently by 2 extractors and cross-checked by a third. Standardized mean difference (SMD) and SE were estimated via Hedges g and synthesized data in a 3-level random-effects meta-analysis. Study data were analyzed from August 2023 to March 2025. MAIN OUTCOMES AND MEASURES: Primary outcomes were clinical response measures. RESULTS: A total of 71 studies met inclusion criteria and included 3246 participants (mean [SD] age; 37.8 [8.0] years; mean [SD] percentage female, 44.1% [17.2%]). Included in the meta-analysis were 63 studies with 2998 participants. For OCD studies, active TMS was associated with better clinical response than sham both with (SMD = -0.51; 95% CI, -0.96 to -0.07; P = 0.04) and without (SMD = -0.29; 95% CI, -0.40 to -0.17; P < .001) symptom provocation. For nicotine use, active TMS was associated with better clinical response than sham when used with (SMD = -0.56; 95% CI, -1.12 to 0; P = .05) but not without (SMD = -0.35; 95% CI, -0.74 to 0.04; P = .08) symptom provocation. For OCD studies, the estimated expected added effect of provocation was SMD of -0.22 (95% CI, -0.65 to 0.20; P = .22). In nicotine studies, the estimated expected added effect of provocation was SMD of -0.21 (95% CI, -1.00 to 0.58; P = .57). CONCLUSIONS AND RELEVANCE: Results of this systematic review and meta-analysis suggest that symptom provocation may enhance clinical response to TMS for OCD and nicotine dependence. Studies comparing TMS with and without provocation are critical to establish the causal effect of provocation.
重要性:经颅磁刺激(TMS)是一种用于治疗重度抑郁症、强迫症(OCD)和尼古丁依赖的非侵入性脑刺激形式,对脑回路具有明确的状态依赖性效应。然而,TMS的一个主要问题仍然存在:脑状态是否会影响临床反应? 目的:为了量化症状激发与TMS治疗OCD和尼古丁依赖的临床反应之间的关联,OCD和尼古丁依赖是美国食品药品监督管理局批准的仅有的两种有症状激发的TMS适应症。 数据来源:截至2024年8月30日的PubMed、CINAHL、Embase、PsycInfo。 研究选择:TMS治疗OCD或尼古丁依赖并具有临床结局的随机临床试验。在确定的600项研究中,71项符合纳入标准。 数据提取与综合:数据提取由2名提取人员独立完成,并由第三名人员进行交叉核对。通过Hedges g估计标准化均数差(SMD)和标准误(SE),并在三级随机效应荟萃分析中综合数据。研究数据于2023年8月至2025年3月进行分析。 主要结局与指标:主要结局为临床反应指标。 结果:共有71项研究符合纳入标准,包括3246名参与者(平均[标准差]年龄;37.8[8.0]岁;平均[标准差]女性百分比,44.1%[17.2%])。纳入荟萃分析的有63项研究,共2998名参与者。对于OCD研究,无论有无(SMD=-0.51;95%CI,-0.96至-0.07;P=0.04)症状激发,主动TMS均比假刺激与更好的临床反应相关。对于尼古丁使用,有症状激发时(SMD=-0.56;95%CI,-1.12至0;P=0.05)主动TMS比假刺激与更好的临床反应相关,但无症状激发时(SMD=-0.35;95%CI,-0.74至0.04;P=0.08)则不然。对于OCD研究,激发的估计预期附加效应为SMD=-0.22(95%CI,-0.65至0.20;P=0.22)。在尼古丁研究中,激发的估计预期附加效应为SMD=-0.21(95%CI,-1.00至0.58;P=0.57)。 结论与意义:这项系统评价和荟萃分析的结果表明,症状激发可能会增强TMS治疗OCD和尼古丁依赖的临床反应。比较有和没有激发的TMS的研究对于确定激发的因果效应至关重要。
Cochrane Database Syst Rev. 2015-8-20
Cochrane Database Syst Rev. 2024-8-2
Cochrane Database Syst Rev. 2018-3-16
Cochrane Database Syst Rev. 2018-4-13
Cochrane Database Syst Rev. 2021-9-3
Cochrane Database Syst Rev. 2016-3-12
Cochrane Database Syst Rev. 2016-4-4
Cochrane Database Syst Rev. 2015-3-5
JAMA Psychiatry. 2025-9-1
Prog Neuropsychopharmacol Biol Psychiatry. 2024-6-8
Neuropsychopharmacology. 2024-3
Neurosci Biobehav Rev. 2023-12